Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with thyroid cancer and known measurable (\>1cm) distant metastases demonstrating radioiodine uptake on a previous whole body scan~2. Patients planned for a therapeutic activity of 131I after thyroid hormone withdrawal~3. Age \>18 years~4. Previous treatment with radioiodine more than 6 months before inclusion.~5. Serum TSH level \<0.5 mU/L~6. Normal renal function with a creatinine clearance estimation using the Cockcroft-Gault formula \> 60 ml/ml~7. Effective means of contraception for female patient, at risk of pregnancy~8. Written informed consent~Exclusion Criteria:~1. Patients whose majority of tumoral lesions disclose FDG uptake without radioactive iodine uptake~2. Iodine excess (\< 50 μg/dl)~3. Large or diffuse bone or brain metastases~4. Patients with multiple small tumor foci less than 1 cm in diameter, such as miliary spread to the lungs~5. Patients already included in a therapeutic trial with an experimental medicine~6. Pregnancy and breast feeding patients~7. Subject with any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures~8. Treatment with antivitamin k

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TSH stimulation (Type: OTHER): rh TSH stimulation followed by thyroid hormon withdrawal

Based on this trial design, predict the completion outcome and termination type (if applicable).